Omniab logo

Omniab share price today

(OABI)

Omniab share price is $3.5 & ₹297.42 as on 21 Dec 2024, 2.30 'hrs' IST

$3.5

Market is closed - opens 8 PM, 23 Dec 2024

View live Omniab share price in Dollar and Rupees. Guide to invest in Omniab from India. Also see the sentimental analysis on Indian investors investing in Omniab. Get details on the Indian mutual funds that are investing in Omniab. Get Analyst recommendations and forecasts along with all the Omniab's financials.

Omniab share price movements

  • Today's Low: $3.50
    Today's High: $3.69

    Day's Volatility :5.02%

  • 52 Weeks Low: $3.43
    52 Weeks High: $6.72

    52 Weeks Volatility :48.92%

Omniab Returns

PeriodOmniab IncIndex (Russel 2000)
3 Months
-17.84%
0.0%
6 Months
-13.79%
0.0%
1 Year
-42.9%
0.0%
3 Years
45.23%
-19.7%

Omniab Key Statistics

in dollars & INR

Previous Close
$3.5
Open
$3.5
Today's High
$3.685
Today's Low
$3.5
Market Capitalization
$423.5M
Today's Volume
$803.5K
52 Week High
$6.715
52 Week Low
$3.43
Revenue TTM
$20.4M
EBITDA
$-58.7M
Earnings Per Share (EPS)
$-0.62
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-20.45%

How to invest in Omniab from India?

It is very easy for Indian residents to invest directly in Omniab from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Omniab stock in both Indian Rupees (INR) and US Dollars (USD). Search for Omniab or OABI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Omniab or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Omniab shares which would translate to 0.243 fractional shares of Omniab as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Omniab, in just a few clicks!

Returns in Omniab for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Omniab investment value today

Current value as on today

₹1,45,100

Returns

₹45,100

(+45.1%)

Returns from Omniab Stock

₹42,904 (false-42.9%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Omniab

-44%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Omniab on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -44% less investors are searching Omniab in the last 30 days versus the previous period.

Global Institutional Holdings in Omniab

  • Avista Capital Holdings LP

    13.07%

  • HHG PLC

    6.50%

  • BlackRock Inc

    5.82%

  • Vanguard Group Inc

    4.29%

  • Macquarie Group Ltd

    3.57%

  • Chicago Capital, LLC

    2.61%

Analyst Recommendation on Omniab

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Omniab(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Omniab

What analysts predicted

Upside of 175.0%

Current:

$3.50

Target:

$9.63

Insights on Omniab

  • Price Movement

    In the last 3 months, OABI stock has moved down by -20.8%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 7.61M → 4.17M (in $), with an average decrease of 45.2% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -13.63M → -16.37M (in $), with an average decrease of 20.1% per quarter
  • OABI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 76.4%
  • Price to Sales

    ForOABI every $1 of sales, investors are willing to pay $17.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Omniab Financials in INR & Dollars

FY19Y/Y Change
Revenue
$18.3M
-
Net Income
$-13.6M
-
Net Profit Margin
-74.18%
-
FY20Y/Y Change
Revenue
$23.3M
↑ 27.02%
Net Income
$-17.6M
↑ 29.2%
Net Profit Margin
-75.46%
↓ 1.28%
FY21Y/Y Change
Revenue
$34.7M
↑ 49.34%
Net Income
$-27.0M
↑ 54.02%
Net Profit Margin
-77.82%
↓ 2.36%
FY22Y/Y Change
Revenue
$59.1M
↑ 70.02%
Net Income
$-22.3M
↓ 17.41%
Net Profit Margin
-37.8%
↑ 40.02%
FY23Y/Y Change
Revenue
$34.2M
↓ 42.17%
Net Income
$-50.6M
↑ 126.65%
Net Profit Margin
-148.16%
↓ 110.36%
Q2 FY23Q/Q Change
Revenue
$6.9M
↓ 58.95%
Net Income
$-14.7M
↑ 141.44%
Net Profit Margin
-212.04%
↓ 175.99%
Q3 FY23Q/Q Change
Revenue
$5.5M
↓ 21.15%
Net Income
$-15.7M
↑ 6.86%
Net Profit Margin
-287.35%
↓ 75.31%
Q4 FY23Q/Q Change
Revenue
$4.8M
↓ 11.96%
Net Income
$-14.1M
↓ 10.71%
Net Profit Margin
-291.44%
↓ 4.09%
Q1 FY24Q/Q Change
Revenue
$3.8M
↓ 21.17%
Net Income
$-19.0M
↑ 34.92%
Net Profit Margin
-498.84%
↓ 207.4%
Q2 FY24Q/Q Change
Revenue
$7.6M
↑ 100.32%
Net Income
$-13.6M
↓ 28.11%
Net Profit Margin
-179.03%
↑ 319.81%
Q3 FY24Q/Q Change
Revenue
$4.2M
↓ 45.21%
Net Income
$-16.4M
↑ 20.12%
Net Profit Margin
-392.45%
↓ 213.42%
FY19Y/Y Change
Profit
$18.3M
-
FY20Y/Y Change
Profit
$23.3M
↑ 27.02%
FY21Y/Y Change
Profit
$19.8M
↓ 14.99%
FY22Y/Y Change
Profit
$42.8M
↑ 116.52%
FY23Y/Y Change
Profit
$34.2M
↓ 20.23%
Q2 FY23Q/Q Change
Profit
$2.1M
↓ 83.38%
Q3 FY23Q/Q Change
Profit
$633.0K
↓ 69.65%
Q4 FY23Q/Q Change
Profit
$-112.0K
↓ 117.69%
Q1 FY24Q/Q Change
Profit
$-1.1M
↑ 925.0%
Q2 FY24Q/Q Change
Profit
$1.5M
↓ 231.79%
Q3 FY24Q/Q Change
Profit
$4.2M
↑ 175.74%
FY19Y/Y Change
Operating Cash Flow
$-5.2M
-
Investing Cash Flow
$-12.1M
-
Financing Cash Flow
$17.3M
-
FY20Y/Y Change
Operating Cash Flow
$3.6M
↓ 169.66%
Investing Cash Flow
$-27.0M
↑ 123.07%
Financing Cash Flow
$23.4M
↑ 35.11%
FY21Y/Y Change
Operating Cash Flow
$-5.7M
↓ 256.73%
Investing Cash Flow
$-4.0M
↓ 85.08%
Financing Cash Flow
$9.7M
↓ 58.49%
FY22Y/Y Change
Operating Cash Flow
$-3.6M
↓ 36.76%
Investing Cash Flow
$-73.3M
↑ 1721.44%
Financing Cash Flow
$110.7M
↑ 1041.99%
Q2 FY23Q/Q Change
Operating Cash Flow
$-10.0M
↓ 136.2%
Investing Cash Flow
$7.8M
↓ 120.93%
Financing Cash Flow
$478.0K
↓ 145.74%

Omniab Technicals Summary

Sell

Neutral

Buy

Omniab is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Omniab Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Omniab Inc
-10.71%
-13.79%
-42.9%
45.23%
45.23%
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.38%
12.23%
86.41%
Biontech Se
4.48%
30.56%
7.97%
-55.71%
237.85%
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.37%
26.29%
108.55%
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-2.55%
77.79%
80.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Omniab Inc
NA
NA
NA
-0.58
-0.2
-0.14
NA
2.43
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Omniab Inc
Buy
$423.5M
45.23%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
86.41%
17.51
33.61%
Biontech Se
Buy
$26.7B
237.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
108.55%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.12%
32.84
-4.51%

About Omniab

the omniab discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
Organization
Omniab
Employees
106
CEO
Mr. Matthew W. Foehr
Industry
Healthcare

Management People of Omniab

NameTitle
Mr. Matthew W. Foehr
President, CEO & Director
Mr. Kurt A. Gustafson
Executive VP of Finance & CFO
Mr. Charles S. Berkman J.D.
Chief Legal Officer & Secretary
Ms. Cia McCaffrey
Vice President of People & Talent
Dr. Bill Harriman Ph.D.
Senior Vice President of Antibody Discovery
Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D.
Senior Vice President of Technical Operations & Genetics
Dr. Christel Iffland Ph.D.
Senior Vice President of Antibody Technologies
Dr. Douglas S. Krafte Ph.D.
Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
Ms. Donna Ventura CPA
Senior VP & Corporate Controller

Important FAQs about investing in Omniab from India :

What is Omniab share price today?

Omniab share price today stands at $3.50, Open: $3.50 ; Previous Close: $3.50 ; High: $3.69 ; Low: $3.50 ; 52 Week High: $6.72 ; 52 Week Low: $3.43. The stock opens at $3.50, after a previous close of $3.50. The stock reached a daily high of $3.69 and a low of $3.50, with a 52-week high of $6.72 and a 52-week low of $3.43.

Can Indians buy Omniab shares?

Yes, Indians can invest in the Omniab (OABI) from India.

With INDmoney, you can buy Omniab at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Omniab at zero transaction cost.

How can I buy Omniab shares from India?

It is very easy to buy Omniab from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Omniab be purchased?

Yes, you can buy fractional shares of Omniab with INDmoney app.

What are the documents required to start investing in Omniab stocks?

To start investing in Omniab, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Omniab

Today’s highest price of Omniab (OABI) is $3.69.

Today’s lowest price of Omniab (OABI) is $3.50.

What is today's market capitalisation of Omniab

Today's market capitalisation of Omniab OABI is 423.5M

What is the 52 Week High and Low Range of Omniab

  • 52 Week High

    $6.72

  • 52 Week Low

    $3.43

What are the historical returns of Omniab?

  • 1 Month Returns

    -10.71%

  • 3 Months Returns

    -13.79%

  • 1 Year Returns

    -42.9%

  • 5 Years Returns

    45.23%

Who is the Chief Executive Officer (CEO) of Omniab

Mr. Matthew W. Foehr is the current Chief Executive Officer (CEO) of Omniab.